Entera Bio Reports Q1 2025 Financial Results and Strategic Developments

Entera Bio ( (ENTX) ) has released its Q1 earnings. Here is a breakdown of the information Entera Bio presented to its investors.

Entera Bio Ltd. is a clinical-stage biotechnology company based in Israel, focused on developing oral tablet formats of peptides or protein replacement therapies primarily for chronic medical conditions. The company recently released its earnings report for the quarter ending March 31, 2025, highlighting significant financial activities and strategic developments. Entera Bio reported a net loss of $2.567 million for the quarter, with operating expenses totaling $2.563 million. The company raised $13.337 million through financing activities, which included the issuance of ordinary shares under an ATM program and a collaboration agreement with OPKO. Entera Bio’s management remains optimistic about the company’s future, with plans to continue developing its product candidates and exploring strategic partnerships to secure additional funding. The company is preparing for a Phase 3 study for its leading product candidate, EB613, and is actively collaborating with OPKO on developing oral peptide treatments.